Incyte Saham

Incyte Goodwill

Goodwill dari Incyte (INCY) pada 16 Agu 2026 adalah 133,00 Juta. USD. Tahun sebelumnya, Goodwill adalah 155,59 Juta. USD — perubahan sebesar -14,52% (lebih rendah).

Goodwill

133,00 Juta.USD

YoY

-14,52%

Terakhir Diperbarui:

Goodwill dari Incyte adalah 2026 133,00 Juta. USD. Goodwill dari Incyte adalah 2025 155,59 Juta. USD. Menurun -14,52% lebih rendah dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Incyte Analisis saham

Apa yang dilakukan Incyte? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Incyte

Goodwill Incyte adalah 133,00 Juta. USD pada tahun 2026.

Goodwill dari Incyte berubah dari 155,59 Juta. USD menjadi 133,00 Juta. USD, mewakili perubahan -14,52%. Nilainya lebih rendah daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Goodwill Incyte sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Goodwill adalah premi yang dibayarkan di atas nilai pasar wajar dalam akuisisi. Ini mewakili nilai tidak berwujud seperti pengenalan merek, hubungan pelanggan, dan kekayaan intelektual.

USD Goodwill adalah faktor kunci bagi investor. Perubahan metrik ini dapat menunjukkan fundamental yang membaik atau memburuk, secara langsung memengaruhi harga saham. Di Eulerpool, Anda dapat melacak Incyte Goodwill secara historis dan real-time.

Access this data via the Eulerpool API

Neraca — Incyte

Semua Metrik Kunci — Incyte